Abstract
Crohn’s disease (CD) is a chronic, disabling, progressive and destructive disease. The general goal of conventional step-up strategy in CD treatment is to treat and control symptoms. This strategy did not change the disease course and is now being replaced with a treat-to-target approach. Achieving deep remission (clinical remission and absence of mucosal ulcerations) is the target in CD in 2014. Inducing and maintaining deep remission is needed to prevent long-term outcomes such as bowel damage and disability in CD. Diagnostic delay is a common issue in CD and is associated with an increased risk of bowel damage over time. Identification of poor prognostic factors, risk stratification together with the development of “red flags” may result in early intervention with disease-modifying agents such as anti-TNF agents with the final aim of preventing overtreatment and avoiding undertreatment. Similar to rheumatoid arthritis, by catching the therapeutic window of opportunity in early CD and achieving deep remission, this could be the best way to change disease course (hospitalizations, surgeries, bowel damage, and disability) and patients’ life.
Keywords: Crohn’s disease, early disease, inflammatory bowel disease, therapy.
Current Drug Targets
Title:Catching the Therapeutic Window of Opportunity in Early Crohn`s Disease
Volume: 15 Issue: 11
Author(s): Silvio Danese, Gionata Fiorino, Carlos Fernandes and Laureal Peyrin-Biroulet
Affiliation:
Keywords: Crohn’s disease, early disease, inflammatory bowel disease, therapy.
Abstract: Crohn’s disease (CD) is a chronic, disabling, progressive and destructive disease. The general goal of conventional step-up strategy in CD treatment is to treat and control symptoms. This strategy did not change the disease course and is now being replaced with a treat-to-target approach. Achieving deep remission (clinical remission and absence of mucosal ulcerations) is the target in CD in 2014. Inducing and maintaining deep remission is needed to prevent long-term outcomes such as bowel damage and disability in CD. Diagnostic delay is a common issue in CD and is associated with an increased risk of bowel damage over time. Identification of poor prognostic factors, risk stratification together with the development of “red flags” may result in early intervention with disease-modifying agents such as anti-TNF agents with the final aim of preventing overtreatment and avoiding undertreatment. Similar to rheumatoid arthritis, by catching the therapeutic window of opportunity in early CD and achieving deep remission, this could be the best way to change disease course (hospitalizations, surgeries, bowel damage, and disability) and patients’ life.
Export Options
About this article
Cite this article as:
Danese Silvio, Fiorino Gionata, Fernandes Carlos and Peyrin-Biroulet Laureal, Catching the Therapeutic Window of Opportunity in Early Crohn`s Disease, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140908125738
DOI https://dx.doi.org/10.2174/1389450115666140908125738 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Homocysteine and Cerebral Stroke in Developing Countries
Current Medicinal Chemistry Optimization of Site Targeted Zolmitriptan Delivery Using Polyox N12K and Methacrylic Acid
Current Drug Therapy Role of Micronutrients: Boron and Molybdenum in Crops and in Human Health and Nutrition
Current Nutrition & Food Science Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Advances in Treating the Ischaemic Diabetic Foot
Current Vascular Pharmacology The Journey of the Non-Vascular Relief for Migraine: From ‘Triptans’ To ‘Ditans’
Current Clinical Pharmacology 8-Hydroxyquinoline and Hydroxamic Acid Inhibitors of Botulinum Neurotoxin BoNT/A
Current Topics in Medicinal Chemistry Disaster Psychiatry: Good Intentions Seeking Science and Sustainability
Adolescent Psychiatry Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry A Clinical Perspective of Soluble Epoxide Hydrolase Inhibitors in Metabolic and Related Cardiovascular Diseases
Current Molecular Pharmacology Quetiapine to Treat Agitation in Dementia: A Randomized, Double-Blind,Placebo-Controlled Study
Current Alzheimer Research Brain Tumor-Related Epilepsy
Current Neuropharmacology Editorial Review (Thematic Issue: An Update on Central Sensitivity Syndromes and the Issues of Nosology and Psychobiology)
Current Rheumatology Reviews Elucidation of Pathophysiology and Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry Inflammatory Bowel Disease: Etiology, Pathogenesis and Current Therapy
Current Pharmaceutical Design Role of Androgens in Womens Sexual Function & Dysfunction: What Have We Learned in Six Decades?
Current Women`s Health Reviews Glaucoma Disease: A Survey
Current Medical Imaging Sulforaphane Treatment of Young Men with Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry Role of Genetic Factors in Statins Side-Effects
Cardiovascular & Hematological Disorders-Drug Targets